Phase 4 N=36 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
Bariatric Surgery Candidate · Bone Loss
Primary: Percentage Change in Total Hip Bone Mineral Density — 0.60; -6.44 percentage of change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Pilot Study of TearCare System - Long-Term Extension
Dry Eye Syndromes
Primary: Mean Change in Tear Break-Up Time From Extension Study Baseline to Month 1 — 12.4 seconds
N/A N=12 A Study to Determine Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Change in Insulin Sensitivity Assessed as Glucose Infusion Rates — 8.6; 8.1 mg/kg FFM/min — p=<0.01
Phase 3 N=179 Effect of Preoperative Tamsulosin on Postoperative Urinary Retention
Postoperative Retention of Urine
Primary: Number of Participants With Postoperative Urinary Retention — 14; 16 Participants
Phase 2 N=25 Defining a PK and PD Model for Peripheral Analgesia After IV Oxytocin
Acute Pain · Chronic Pain · Healthy Volunteer
Primary: Verbal Pain Score at the End of 5 Minutes of Skin Heating — 3.3; 3.1; 3.4; 3.1 score on a scale
Phase 2 N=391 A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score — -16.1; -18.5; -14.2 score on a scale — p=0.2925
N/A N=219 Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES)
Renal Stone · Ureteral Stone
Primary: Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-intensity at 7 to 10 Days — 4.28; 2.92 T-score — p=0.26
Phase 1 N=24 Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK
Hepatic Impairment
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of M2951 — 186; 232; 362 hour*nanogram per milliliter (h*ng/mL)
N/A N=61 Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Glycemic Outcomes — 36.3; 35.7; 37.5; 35.8 Percent of coefficient of variation
Phase 2 N=68 Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
NSCLC Non-small Cell Lung Cancer
Primary: Event-free Survival (EFS) Rate — 73.4 percentage of participants
N/A N=36 mPCST for BMT Patients
Stem Cell Transplant
Primary: Feasibility as Measured by the Overall Percentage of Completed Sessions — 83 percentage of sessions
N/A N=16 BabyStrong Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Paired Bottle Feeding to Improve Oral Feeding
Infant Feeding Problems, taVNS
Primary: Bradycardia — 0; 0; 0; 0 Participants
Phase 2 N=16 Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
Intrahepatic Cholangiocarcinoma
Primary: Number of Participants With Tumor Complete Response (CR) — 7 Participants
Phase 3 N=616 TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia
Hematologic Neoplasms · Hemorrhage · Hematopoietic Stem Cell Transplantation
Primary: The Proportion of Patients Who Die or Have Bleeding of WHO Grade 2 or Above by WHO Criteria During the First 30 Days From the First Dose of Trial Treatment, or Planned…
Phase 2 N=36 Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age
Central Nervous System Diseases · Pediatric Disorder · Body Indication
Primary: Area Under the Curve (AUCinf) — 392.3; 493.3 h.mg/L